Data on the comparative usefulness of medications commonly prescribed to individuals with alcohol use disorder (AUD) are scarce. This study compared the association between antidepressants, relapse-preventive AUD medication, both, and neither on the risk of subsequent alcohol-related hospitalization in individuals with severe AUD. This retrospective analysis of Swedish nationwide register data used Cox (primary analysis) and logistic (sensitivity analysis) regression models to assess the associations between medication exposure (antidepressants, AUD medication, both, neither) and risk of subsequent alcohol-related hospitalization. The analysis included data on 14,026 individuals who were admitted to the hospital for severe AUD between 2009 and 2020. Antidepressants were not significantly associated with a lower risk of subsequent alcohol-related hospitalization (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.82-1.08), but AUD medication was (HR = 0.61, 95% CI = 0.54-0.69), as were antidepressants plus AUD medication (HR = 0.63, 95% CI = 0.45-0.87) (reference: exposure to neither). Pairwise comparisons showed that AUD medication was associated with a lower risk of hospitalization than antidepressants (HR = 0.65, 95% CI = 0.54-0.78). Antidepressants alone were associated with a higher risk than antidepressants plus AUD medication (HR = 1.50, 95% CI = 1.05-2.15). The sensitivity analysis confirmed the association between AUD medication and lower hospitalization risk. Antidepressant monotherapy was not associated with a lower risk of subsequent alcohol-related hospitalization, but relapse-preventive medication for AUD was, both alone and in combination with antidepressants. These findings support the use of relapse-preventive medication to reduce hospitalization risk in individuals with severe AUD and raise questions about the benefit of antidepressant monotherapy for this purpose.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00406-025-01988-z | DOI Listing |
Eur Arch Psychiatry Clin Neurosci
March 2025
Academic Primary Care Centre, Region Stockholm, Sweden.
Data on the comparative usefulness of medications commonly prescribed to individuals with alcohol use disorder (AUD) are scarce. This study compared the association between antidepressants, relapse-preventive AUD medication, both, and neither on the risk of subsequent alcohol-related hospitalization in individuals with severe AUD. This retrospective analysis of Swedish nationwide register data used Cox (primary analysis) and logistic (sensitivity analysis) regression models to assess the associations between medication exposure (antidepressants, AUD medication, both, neither) and risk of subsequent alcohol-related hospitalization.
View Article and Find Full Text PDFAlcohol Clin Exp Res (Hoboken)
March 2025
Department of Psychiatry, Addiction Center, University of Michigan, Ann Arbor, Michigan, USA.
Front-line treatments for alcohol use disorder (AUD) include psychotherapy and medication, and both treatments are underused. However, utilization rates of medications for alcohol use disorder (MAUD) are particularly low. The goal of the present scoping review is to characterize patient perspectives about MAUD to identify barriers to MAUD and potential areas of future work to increase access, initiation, and retention on MAUD.
View Article and Find Full Text PDFPsychedelic Med (New Rochelle)
June 2024
Department of Behavioral Health, Denver Health & Hospital Authority, Denver, Colorado, USA.
Introduction: Alcohol use disorder (AUD) is widespread and problematic in the United States, and current pharmacotherapy options have relatively modest effects. Therefore, novel interventions such as ketamine therapy have gained interest as potentially efficacious options, known to generate unique psychotherapeutic experiences. The present secondary analysis examines the acute subjective experiences-both quantitatively and qualitatively-of clinical trial participants with AUD who received intravenous (IV) ketamine therapy in the hospital setting.
View Article and Find Full Text PDFJ Clin Invest
March 2025
Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, NIH, Bethesda, United States of America.
Background: Despite growing preclinical evidence that glucagon-like peptide-1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl peptidase-4 inhibitors (DPP-4Is) on alcohol intake is largely unknown.
Methods: We conducted a large cohort study using 2008-2023 electronic health records data from the U.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!